DEVELOPMENT OF NOVEL MUCOSAL VACCINE STRATEGIES

新型粘膜疫苗策略的开发

• 批准号: 6289007
• 负责人: BRIAN KELSALL
• 金额: --
• 依托单位: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/6289007
• 关键词: Herpesviridae vaccine; antibody formation; cytokine; cytotoxic T lymphocyte; guinea pigs; herpes simplex virus 2; laboratory mouse; lymphocyte proliferation; molecular cloning; mucosal immunity; vaccine development; vector vaccine; virus DNA

This project focuses on the development of new vaccines for protection against mucosal infections, including herpes simplex virus type 2, the major cause of genital herpes infections. Novel vaccine approaches will be established with model antigens and applied to the development of a vaccine that will provide primary protection against mucosal infection with virulent HSV-2. These will include the cloning and expression of viral genes in vectors for delivery directly to the mucosal immune system, the delivery of candidate naked DNA vaccine constructs to systemic and mucosal sites with novel adjuvants. The work involves cloning candidate viral genes into appropriate vectors, immunizing mice and/or guinea pigs with vaccine candidates, and testing for vaccine efficacy following experimental HSV-2 infections. Immunologic correlates of protection will also be evaluated using standard immunologic assays for antibodies, cytokine production, cell proliferation, and induction of cytotoxic T lymphocytes. - herpes simplex virus, HIV, vaccine, mucosal immunity, DNA, salmonella, acquired immunodeficiency syndrome, immunology, IgA

这个项目的重点是研制防止粘膜感染的新疫苗，包括2型单纯疱疹病毒，这是生殖器疱疹感染的主要原因。将利用模型抗原建立新的疫苗方法，并将其应用于疫苗的开发，该疫苗将提供针对强毒性HSV-2粘膜感染的初级保护。这些将包括在载体中克隆和表达病毒基因以直接传递到粘膜免疫系统，用新型佐剂将候选裸DNA疫苗构建体传递到全身和粘膜部位。这项工作包括将候选病毒基因克隆到适当的载体中，用候选疫苗对小鼠和/或豚鼠进行免疫，以及在实验性HSV-2感染后测试疫苗效力。免疫保护的相关因素也将通过抗体、细胞因子产生、细胞增殖和细胞毒性T淋巴细胞诱导的标准免疫测定来评估。-单纯疱疹病毒、HIV、疫苗、粘膜免疫、DNA、沙门氏菌、获得性免疫缺陷综合征、免疫学、IgA